Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in mAbs
- Vol. 12 (1) , 1770669
Abstract
Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n=5) to intensified processing schemes at both 1000-L (Process B, n=8) and 2000-L scales (Process C, n=3) for the production of a monoclonal antibody by a Chinese hamster ovary cell line. For the upstream part of the process, we implemented an intensified seed culture scheme to enhance cell densities at the seed culture step (N-1) prior to the production bioreactor (N) by using either enriched N-1 seed culture medium for Process B or by operating the N-1 step in perfusion mode for Process C. The increased final cell densities at the N-1 step allowed for much higher inoculation densities in the production bioreactor operated in fed-batch mode and substantially increased titers by 4-fold from Process A to B and 8-fold from Process A to C, while maintaining comparable final product quality. Multiple changes were made to intensify the downstream process to accommodate the increased titers. New high-capacity resins were implemented for the Protein A and anion exchange chromatography (AEX) steps, and the cation exchange chromatography (CEX) step was changed from bind-elute to flow-through mode for the streamlined Process B. Multi-column chromatography was developed for Protein A capture, and an integrated AEX-CEX pool-less polishing steps allowed semi-continuous Process C with increased productivity as well as reductions in resin requirements, buffer consumption and processing times. A cost-of-goods analysis on consumables showed 6.7-10.1 fold cost reduction from the conventional Process A to the intensified Process C. The hybrid intensified process described here is easy to implement in manufacturing and lays a good foundation to develop a fully continuous manufacturing with even higher productivity in the future.Keywords
This publication has 54 references indexed in Scilit:
- Periodic counter‐current chromatography – design and operational considerations for integrated and continuous purification of proteinsBiotechnology Journal, 2012
- Integrated continuous production of recombinant therapeutic proteinsBiotechnology and Bioengineering, 2012
- A new large‐scale manufacturing platform for complex biopharmaceuticalsBiotechnology and Bioengineering, 2012
- Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cellsBiotechnology and Bioengineering, 2011
- High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humansGlycobiology, 2011
- Cell culture processes for monoclonal antibody productionmAbs, 2010
- Maximizing productivity of CHO cell‐based fed‐batch culture using chemically defined media conditions and typical manufacturing equipmentBiotechnology Progress, 2010
- Effects of Elevated pCO2 and Osmolality on Growth of CHO Cells and Production of Antibody-Fusion Protein B1: A Case StudyBiotechnology Progress, 2008
- Production of recombinant protein therapeutics in cultivated mammalian cellsNature Biotechnology, 2004
- Potential of cell retention techniques for large‐scale high‐density perfusion culture of suspended mammalian cellsBiotechnology and Bioengineering, 2003